# A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

> **NCT03275389** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 470 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** D-SUIV cH8/1N1+AS03
- **BIOLOGICAL:** D-SUIV cH5/1N1+AS03
- **BIOLOGICAL:** D-SUIV cH11/1N1+AS03
- **BIOLOGICAL:** D-SUIV cH8/1N1+AS01
- **BIOLOGICAL:** D-SUIV cH5/1N1+AS01
- **BIOLOGICAL:** D-SUIV cH11/1N1+AS01
- **BIOLOGICAL:** D-SUIV cH8/1N1
- **BIOLOGICAL:** D-SUIV cH5/1N1
- **BIOLOGICAL:** D-SUIV cH11/1N1
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Fluarix Quadrivalent

## Key facts

- **NCT ID:** NCT03275389
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-08
- **Primary completion:** 2020-03-26
- **Final completion:** 2020-03-26
- **Target enrollment:** 470 (ACTUAL)
- **Last updated:** 2021-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03275389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03275389, "A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03275389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*